Sudden Cardiac Death (SCD) in Athletes Risk Calculator (Multivariate)

Clinical calculation support · Verify results before clinical use

Clinical assessment

Record clinical warning signs and epidemiological context. This tool does not generate a validated overall SCD probability or composite risk score.

Clinical decision support

Athlete profile

Epidemiological associations are context-specific and must not be interpreted as an individual prediction.

Clinical warning signs

A positive response should prompt appropriate clinical evaluation; these items are not assigned arbitrary points.

Clinical context and limitations

Sudden cardiac death in athletes is uncommon but has important consequences. Risk assessment depends on symptoms, personal and family history, examination, ECG interpretation, and targeted investigations when indicated. A single checklist cannot replace this assessment.

How to use this tool

  • Use the warning-sign checklist to support, not replace, history-taking and clinician assessment.
  • Interpret ECG findings using accepted athlete-specific criteria; normal training-related adaptations should not automatically be labelled abnormal.
  • Known cardiomyopathy, channelopathy, or pre-excitation requires diagnosis-specific assessment rather than a common point total.
  • Do not use the epidemiological associations shown here to make individual clearance, disqualification, or treatment decisions.

Important HCM model limitation

The original ESC HCM Risk-SCD model uses age, maximal LV wall thickness, left atrial diameter, maximal resting/Valsalva LVOT gradient, family history of SCD, NSVT, and unexplained syncope. Current ESC guidance recommends it for primary-prevention risk estimation in HCM patients aged 16 years or older, but the model is not intended for elite/competitive athletes. The estimate also does not replace assessment of additional markers or shared decision-making.

References

Pelliccia A, Sharma S, Gati S, et al.2020 ESC Guidelines on sports cardiology and exercise in patients with cardiovascular disease. European Heart Journal. 2021;42:17–96. doi:10.1093/eurheartj/ehaa605.
Arbelo E, Protonotarios A, Gimeno JR, et al.2023 ESC Guidelines for the management of cardiomyopathies. European Heart Journal. 2023;44:3503–3626. doi:10.1093/eurheartj/ehad194.
O’Mahony C, Jichi F, Pavlou M, et al.A novel clinical risk prediction model for sudden cardiac death in hypertrophic cardiomyopathy (HCM Risk-SCD). European Heart Journal. 2014;35:2010–2020. doi:10.1093/eurheartj/eht439.
Petek BJ, et al.Sudden Cardiac Death in National Collegiate Athletic Association Athletes: A 20-Year Study. Circulation. 2024. PubMed: 37955565.
Clinical disclaimer: This educational decision-support tool does not diagnose disease, calculate an overall validated athlete SCD risk, determine eligibility for sport, or replace specialist assessment. Clinical decisions should incorporate current guidelines, patient preferences, and local protocols. If acute symptoms or collapse occur, seek emergency care.